

INVEST | TEES VALLEY



LIFE SCIENCES & HEALTHCARE



TEES VALLEY
COMBINED
AUTHORITY

TEES VALLEY MAYOR

LIFE SCIENCES & HEALTHCARE SECTOR

The Northern Powerhouse's Health Research Science and Innovation Audit (June 2018) valued the North's life sciences economy at £13.6billion in 2017, marking a 48% increase from £9.2billion in 2016 and at a growth rate 4.8% higher than the national average. Sustained population growth and older demographics, allied to the prevalence of chronic and communicable diseases, are key drivers fuelling the growth of the life sciences industry.

The North East pharmaceutical manufacturing industry contributed £1.04billion of GVA in 2018. Regional GVA in the sector has been increasing year on year and in the past three years (2015 to 2018) has grown by over one third (34% up) in real terms, almost seven times the national increase of just 5%. The region benefits from research and commercial interests across oncology, ageing and health, genetics, plant biotechnology, stem cells and regenerative medicine, infectious diseases, biologics, systems and cell biology and medical devices. It is also one of the UK's leading academic bioscience centres for research, teaching and training.

The Tees Valley is at the forefront of the growing opportunities in life sciences, with four highly regarded NHS trusts, the Centre for Process Innovation's (CPI) flagship National Biologics Manufacturing Centre and Teesside University's National Horizons Centre, all supporting the wealth of global healthcare, biologics and pharmaceutical companies operating here.




TEES VALLEY OPPORTUNITIES

Investor confidence in the area is strong, with life sciences businesses increasingly seeing the Tees Valley as the place to be. Internationally recognised companies such as FUJIFILM Diosynth Biotechnologies and CPI are continuing to invest in the area, alongside SMEs such as Hart Biologicals, Absolute Antibodies and Cambridge Research Biochemicals. The area also has a strong track record of delivering clinical trials, with around 7,250 patients recruited annually.

The National Institute for Health Research has ranked the South Tees Trust in the top 11% of NHS trusts in the country for the number of participants recruited to trials. The clinical research is augmented by strong relationships between academic institutions, industry and the NHS and its supportive innovation network drives and helps to fund collaborative research and development for patient gain.

The Tees Valley has many advantages for investment over other areas. It has the skills available through Teesside University, which produces more than 3,000 health and life sciences and 3,700 computing, engineering and digital technologies graduates each year. The area has an excellent existing infrastructure, with some of the best superfast broadband in the UK, as well as a growing digital cluster that services the key sectors including healthcare and life sciences. Added to this are organisations such as Teesside University, NEPIC, Bionow, the Academic Health Science Network for the North East and North Cumbria and the Tees Valley Combined Authority which all provide an excellent support network allowing companies to prosper here.





INVESTOR CONFIDENCE IN THE TEES VALLEY

Thanks to the region's science-based industries and excellent skills, there is already a number of long established global life science businesses operating in the Tees Valley. Collectively these businesses have invested more than £500million, demonstrating their commitment to the Tees Valley to help deliver against their longer-term growth plans.



FUJIFILM Diosynth Biotechnologies is a world-leading contract manufacturing organisation. It has been based in the Tees Valley since 1996 and has invested more than £100million in the past 20 years. Its Billingham based mammalian cell culture cGMP manufacturing facility was the first of its kind in the UK. As a further sign of FUJIFILM's continued success, FUJIFILM committed a further £60million during 2020 to triple the current capacity of microbial production in Billingham.



The Centre for Process Innovation (CPI) is an open-access, independent innovation centre that supports the development of the UK process industry and UK manufacturing. CPI assists businesses of all sizes, from start-ups through to large multinational corporations, to efficiently deliver innovations as market-ready solutions. By providing state-of-the-art open access facilities and market knowledge, CPI reduces the risks and costs that come with developing new concepts, giving businesses the best chance of success.



MAC Clinical Research (MAC) is a UK provider of outsourced development services to the pharmaceutical and biotechnology industries. Services include pre-clinical drug development, first-in-man studies including manufacturing services and pharmaceutical development. MAC established a late-phase clinical research facility in Stockton-on-Tees during 2017 that focuses on clinical pharmacodynamic modelling to enable MAC scientists to investigate symptoms of disease under controlled laboratory conditions.



GSK researches, develops and manufactures innovative pharmaceutical medicines, vaccines and consumer healthcare products. It has invested £92million at its Barnard Castle site to construct an aseptic sterile facility supporting the manufacture of existing and new biopharmaceutical assets.



Absolute Antibody in Redcar is a specialist in antibody sequencing, engineering and recombinant expression. Its custom antibody sequencing, engineering and expression services are used by leading pharmaceutical, biotechnology and diagnostics companies, as well as by academic researchers worldwide.



Based on Queens Meadow Business Park in Hartlepool, Hart Biologicals manufactures reagents used to investigate the blood clotting function in patients taking blood thinning drugs such as warfarin. Hart Biologicals is now involved in all areas of Coagulation and Platelet Aggregation. Hart Biologicals' sister company, Hart Innovations, supports Hart Biologicals with the increasing high-demand for contract research.



KD Pharma UK, as part of KD Pharma Group, offers CMO services for registered intermediates and API's, ranging from route identification and process development, through to scale-up and production. The KD Pharma Group is a contract manufacturer that develops products in the pharmaceutical and nutraceutical space. It is also one of the largest Omega-3 fatty acid producers in the world with presence in the UK, Norway, Germany, Switzerland and the US.



XL Precision Technologies Ltd is based in Stockton and specialises in the manufacture of precision micro-components for the medical sector. It has made recent investments in laser machining, EDM sink capacity, CNC milling centres and laser welding.



Cambridge Research Biochemicals at Belasis Park in Billingham celebrated its 40th anniversary in July 2020. Cambridge Research Biochemicals produces custom peptides and bespoke antibodies for the pharmaceutical industry. It is the world's second-oldest peptide manufacturer.

CENTRE FOR PROCESS INNOVATION

The Centre for Process Innovation (CPI) is an open-access, independent innovation centre that supports the development of the UK process industry and UK manufacturing.

As part of the UK Government's Strategy for Life Sciences, CPI was selected to be the home of the National Biologics Manufacturing Centre in Darlington. Established in 2015, the £38million centre is helping UK companies develop a competitive foothold in the growing market for biologics. Globally, the biologics market was worth around USD\$255billion in 2019 and is expected to reach USD\$500billion by 2025.

CPI provides state-of-the-art open access facilities and diverse, independent market knowledge to assist businesses of all sizes in efficiently delivering innovations as market-ready solutions. This reduces the risks that come with developing new concepts, giving businesses the best chance of success.

A flexible approach allows CPI to support its partners every step of the way, as innovations grow through concept and technology development, to scale-up and supply chain intervention.

As a leader in innovation, CPI plays a key role in fulfilling the UK's Industrial Strategy to improve economic growth through driving productivity. From biologics and precision medicine to smart materials and formulation, CPI's collaborations with innovators solve the complex industrial challenges of today in a more efficient and sustainable manner.





Case Study

CPI collaborated with Arecor to investigate ways to enhance the compatibility of biologic medicines with drug product containers and thereby potentially improve stability and shelf-life throughout transportation and storage. This project was the first industry partnership undertaken by CPI in association with its £38million National Biologics Manufacturing Centre.

The issue: The components of drug product vials and syringes have been found to have an adverse impact on the stability of some biologics, causing degradation that can render the medicine unsuitable for administration and, in some cases, result in product recalls.

The resolution: This collaboration investigated the effects of selected silicone oils and other primary packaging materials on the ability of proteins to enhance understanding of container-related causes of degradation and the use of novel formulations to mitigate these effects. CPI allowed Arecor to gain crucial insights into the nature of undesirable effects and make an important step toward effective formulation strategies to mitigate them. The ability to stabilise therapeutic proteins as demonstrated during this project can provide great benefit for the global biologics manufacturing supply chain.





NHS FOUNDATION TRUSTS

The NHS in the Tees Valley includes four Foundation Hospital Trusts comprising North Tees and Hartlepool, South Tees, County Durham and Darlington, along with the Tees, Esk and Wear Valleys. Between them they employ around 20,000 staff, have a turnover of more than £1 billion a year and are regularly ranked in the top 40 best Trusts in the country. Importantly, each of the Trusts continues to grow its participation in clinical trials and can demonstrate a successful track record in trials recruitment and delivery with commercial life science partners.

North Tees and Hartlepool NHS Foundation Trust

North Tees and Hartlepool NHS Trust provides hospital and community-based healthcare to circa 400,000 people living in the Tees Valley and surrounding areas. It has expertise in breast and bowel screening. With a turnover of around £300 million, the Trust employs more than 5,000 medical, nursing, clinical and non-clinical support staff. Global site management organisation Synexus operates a clinical trials research site at the North Tees Trust's Middlefield Centre. Marking its ninth site opening in the UK, Synexus offers biopharmaceutical and contract research organisations capacity to recruit patients for clinical studies in key development market.

Clinical research: The Trust was involved in 74 portfolio studies in 2018/19, successfully recruiting 1,834 patients to these trials. 74% of patients were recruited into the more complex interventional studies. This is a high figure of interventional trials compared with either the regional (32%) or national figure (24%). There were six commercial studies active in the Trust during 2018/19 within Cardiology, Cancer and Obstetrics and Gynaecology. The research and development team have contributed towards 15 national COVID-19 research trials since March 2020. This culminated in the award of "Outstanding Research Contribution" from the Clinical Research Network North East and North Cumbria for the Trust's contribution to the RECOVERY trial – a national clinical trial to identify treatments beneficial for people hospitalised with suspected or confirmed COVID-19.

County Durham and Darlington NHS Foundation Trust

County Durham and Darlington NHS Foundation Trust is one of the largest integrated care providers in England, serving a population of 700,000 people. The Trust has a workforce of more than 7,000 and provides acute hospital services at Darlington Memorial Hospital. Darlington Memorial Hospital has undertaken high levels of research over the past few years in areas of cardiology, gastroenterology and liver disease, cancer (particularly breast cancer), stroke, diabetes, rheumatology and dermatology. There is also strong research growth in anaesthetics, obstetrics and gynaecology, colorectal surgery, ophthalmology and orthopaedics.

Clinical research: The number of patients recruited to participate in research trials increased to over 2,000 across 95 clinical trials in 2019/20. This included trials across 25 specialties including cancer, cardiology, critical care, dermatology, ENT, diabetes, gastro intestinal, hepatology, obstetrics and gynaecology, paediatrics, respiratory and stroke services. During the year the Trust joined forces with neighbouring trusts at North and South Tees to form the Durham and Tees Valley Research Alliance, which shares resources to maximise the range and scope of the research collectively delivered.



South Tees Hospitals NHS Foundation Trust

South Tees Hospitals NHS Foundation is the largest Trust in the Tees Valley, serving populations in Middlesbrough, Redcar and Cleveland and North Yorkshire. It has a workforce of almost 9,000 staff and provides a range of specialist regional services to 1.5million people. The Trust runs the James Cook University Hospital in Middlesbrough, the Friarage Hospital in Northallerton and a range of community services across the Tees Valley. It has expertise in heart disease, neurosciences, children's and maternity services, renal medicine, cancer services and spinal injuries and is the major trauma centre for the southern part of the northern region.

Its £35million intensive cancer treatment facility is at the cutting edge of European clinical practice. James Cook University Hospital has links with Teesside University and the universities of Durham and Newcastle. The academic division also has the research and development directorate and part-hosts the research design services for the northern region.

Investment in teaching is also a key pillar of the South Tees NHS Trust. During 2018, Newcastle University partnered with South Tees Hospitals NHS Foundation Trust to invest £1million to further enhance medical student training, boosting the total number of medical students from Newcastle University in the Tees Valley to around 300 a year.

South Tees NHS Trust is also a leading partner in the Academic Health Science Network (AHSN) and a member of the Clinical Research Network for the North East and North Cumbria. It is also the award holder for several ongoing multi-centre National Institute for Health Research (NIHR) grant funded projects, providing support in sponsorship, study co-ordination/management and research delivery.

Clinical research: 3,718 people participated in 196 clinical research studies at South Tees Trust in 2018/19, with the Trust ranking 3rd in the region and in the top 25% of Acute Trusts. A total of 257 of these patients were recruited into 33 commercial clinical trials in 12 clinical specialisms. The active participation in research is reflected in data published by the National Institute of Health Research, which ranks the South Tees Trust in the top 11% of NHS Trusts in the country.

Tees, Esk and Wear Valleys Foundation Trust

Tees Esk and Wear Valleys NHS Trust was the first North East mental health trust to achieve Foundation Trust status. It provides a range of mental health, learning disability and substance misuse services for the 660,000 people that live in the Tees Valley, as well as one million more in County Durham and North Yorkshire. The Trust has approximately 170 sites and employs 5,700 staff.

FUJIFILM DIOSYNTH BIOTECHNOLOGIES



FUJIFILM Diosynth Biotechnologies is a world-leading cGMP Contract Development and Manufacturing organisation. It provides support to partners in the biopharmaceutical industry with the development and production of biologics, vaccines and gene therapies. It has been based in the Tees Valley since 1996 with its UK headquarters located at Billingham.


FUJIFILM has made a string of investments into the Tees Valley during the past five years. In 2017 it opened a brand new £7million state-of-the-art biotech facility at Wilton, Redcar. The 10,000ft² cell culture Process Development Laboratory is dedicated to support the Saturn™ mAb Platform cell culture process development activities. The Saturn™ mAb Platform is designed to enable rapid access to process development and manufacturing capacity. By dedicating these facilities and bringing new technologies FUJIFILM supports its customers in the rapid delivery of monoclonal antibody therapies to patients all over the world.

In 2018, marking a further sign of FUJIFILM's continued success in the Tees Valley, FUJIFILM committed a further £14.5million towards the establishment of a new Bio-campus in Billingham across a 3.5-hectare site. This investment was supported by £1million grant from the Tees Valley Business Compass capital support scheme, within a £7million package of support provided by the Tees Valley Combined Authority. The investment is the next stage in FUJIFILM's UK growth plans and will see the construction of a new office and laboratory space.

FUJIFILM's latest investment of £60million was sanctioned in March 2020 and will lead to a tripling of microbial production capacity at Billingham, enabling it to meet the increased demand of microbial expressed therapies. FUJIFILM's continued expansion at Billingham will include a new production line equipped with 2 X 2000L fermenters and a modular purification suite. The utilities at the facility will also be upgraded to accommodate for high volume production.

FUJIFILM is also pioneering the UK's response to the COVID-19 pandemic, with confirmation in August 2020 that it will manufacture the antigen component of NVX-CoV2373, Novavax's COVID-19 vaccine candidate. Novavax has agreed terms with the UK Government for the purchase of 60 million doses of NVX-CoV2373 and a Phase 3 clinical trial to assess the efficacy of the vaccine in the UK population. FUJIFILM's Billingham site has the capacity to produce up to 180 million doses annually, which further boosts the global supply of NVX-CoV2373 for additional markets. Production at the Billingham site will begin in early 2021.

| ACADEMIC RESEARCH



Businesses in the Tees Valley operate in an international economic environment, with internal innovation central to the development of their products and processes. However, it is widely recognised that being part of a vibrant innovation hub is a critical source of external knowledge and the Tees Valley is home to a number of institutes that can produce high-quality research on health and social care.

Fuse is a virtual centre operating across five universities in the North East, including Teesside University. It is one of only five Public Health Research Centres of Excellence in the UK with the aim to deliver world-class public health research.

The focus of Fuse is on working with policy makers and practitioners, enabling research findings to be understood and applied to public health issues, for example diet and exercise and socio-economic inequalities.

Teesside University – School of Health & Life Sciences

The School of Health & Life Sciences aims to progress interdisciplinary research across the university and in partnership with external groups and bodies to produce the quality research that businesses need. The dissemination of high-quality outputs at local, national and international levels is coordinated within two major strands; rehabilitation sciences and public health. Two example studies are highlighted below.

1. Evidence-based physiotherapy guidelines for contracted frozen shoulder

Teesside University has developed the first ever evidence-based physiotherapy guidelines for the diagnosis, assessment and physiotherapy management of contracted frozen shoulder (CFS). CFS is a condition that painfully restricts movement and affects up to 10% of working-age adults in the UK and costs the NHS around £13.5million annually. The guidelines are being used nationally to help improve the clinical management of CFS and patients' experiences of the condition.

2. Exercise improving surgical outcomes

Teesside University is active in clinical research into exercise science and health research. Specifically, work spans two main themes, exercise testing/training studies in a variety of patient groups and industry-sponsored clinical trials in patients with chronic intractable pain. In the exercise prehabilitation and rehabilitation research area, the latest project is a feasibility study of high-intensity interval exercise training before abdominal aortic aneurysm surgery. Related studies include a trial of exercise rehabilitation in survivors of critical illness, in which clinically significant benefits in physical fitness have been observed.

| THE RIGHT SITES

The Tees Valley is home to a number of vibrant business parks with excellent laboratory facilities and office space for growing life sciences businesses. Pharmaceutical manufacturing requirements can also be satisfied by the availability of large fully serviced and strategically located sites across the Tees Valley.

Central Park

This is a 30-hectare site in Darlington adjacent to the East Coast Main Line, offering excellent links to London and Edinburgh. It is home to CPI's £38million National Biologics Manufacturing Centre, Teesside University's Darlington campus, Darlington College and Business Central One, which provides modern start-up office space for growth businesses.

Central Park is also home to Teesside University's £22.3million National Horizons Centre. The National Horizons Centre has been established to support the growth of the bioscience, biotechnology, health technology

and related sectors with specialist education and training. The National Horizons Centre supports industry-led research and innovation in analytics, data science and digital technologies.

New business accommodation at Central Park will be created imminently with the build of Business Central Two. This development will provide new start-up office space combined with clean space or laboratories, adding further to Central's Park's existing bioscience skills and innovation assets.

Connectivity

The region's central location makes it easy to reach the whole of the UK. Darlington Station connects the region to all corners of the UK, with half-hourly rail services to London taking less than two and a half hours and Edinburgh in two hours. TransPennine Express services connect Middlesbrough and Yarm to York, Leeds and Manchester.

Teesside International Airport is only an 11 minute drive from Darlington Train Station. The airport offers daily connections to London Heathrow in less than an hour, as well as Belfast, Southampton, Newquay and Aberdeen. It also connects the Tees Valley to more than 180 global destinations through international hubs at Heathrow and Schiphol.



Belasis Business Park

In Billingham, this is home to Cambridge Research Biochemicals and adjacent to FUJIFILM Diosynth Biotechnologies. It provides office space in a range of 33 detached and terraced units ranging in size from 650ft² up to 18,162ft². Around 20 hectares of land is available for new development.

The Wilton Centre

The Wilton Centre, Redcar, is a major science park. The site totals 30 hectares and hosts more than 50 tenants. There is more than 250,000ft² of quality open plan, modular office and lab space available. The site offers a range of equipment on site to suit pharma, med-tech and healthcare occupants. These plug-and-play units enable companies to develop cutting-edge products and processes, while reducing peripheral start-up costs such as provision of industrial services and purchase of general laboratory equipment.

Queens Meadow Business Park

Queens Meadow Business Park, Hartlepool, covers 65 hectares and offers high-class business units within a modern landscaped environment. There is more than 13 hectares of prime development land as well as existing units available for immediate occupation.

Kirkleatham Business Park

Kirkleatham Business Park, Redcar, is situated close to the renowned Wilton International complex with its cluster of chemical and process industry companies.

Tees Advanced Manufacturing Park

Tees Advanced Manufacturing Park (TeesAMP), pictured, in Middlesbrough, includes 180,000sqft of newly created, high specification manufacturing space. The site is already home to the TWI Technology Centre which in May 2020 announced a partnership with Teesside University to host a new Industrial Decarbonisation and Hydrogen Innovation Centre. The second phase of the TeesAMP development will provide flexible building opportunities for new investors.



| THE RIGHT SKILLS

The Tees Valley is well-placed to provide the skills required for life sciences companies choosing to invest here.

Teesside University is one of the UK's fastest-growing universities. It has an excellent record of employer engagement, a number of Knowledge Transfer Partnerships with local businesses and is recognised as one of the best universities for business in Britain. It is ranked 39th out of 102 institutions for Biosciences in the Guardian University Guide 2020 (121 institutions participated).

There are more than 4,200 full-time undergraduate students studying programmes including Higher & Degree Apprenticeships in the School of Health & Life Sciences, which works closely with the NHS Foundation and independent sector partners in commissioning courses. The School has considerable strength in health care practice through a comprehensive range of programmes, from nursing and radiography to dentistry.

A further 3,700+ full-time students study courses in Computing, Engineering and Digital Technologies. In

addition, 3,400+ students take continuing professional development short courses each year and 1,000+ are studying for postgraduate qualifications.

Teesside University Partnership

Teesside University and the Tees Valley Combined Authority share an ambition to drive economic growth by supporting local businesses. The Teesside University Partnership, signed in January 2018, formalises the relationship between the two organisations which have worked together for many years to deliver joint projects and initiatives that help local residents and businesses. It is a unique agreement that will enable the creation of the high-level skills that local businesses need to thrive, by attracting and retaining more graduates. It will also help increase the scale-up potential for local businesses and increase innovation capacity, giving businesses here a competitive edge over other regions.



NATIONAL HORIZONS CENTRE

Opened in spring 2019, Teesside University's National Horizons Centre at Central Park in Darlington is a nationally significant, purpose-built asset designed to address UK technology sector growth through the provision of world class facilities and equipment for hands-on training.

It has been constructed to address skills shortages in the biosciences, biotechnology, health technology and related sectors by growing the number of technicians, graduates and post-graduates and enable continuous professional development for those re-training or in employment.

Its creation also facilitates growth through industry-led research and innovation, enabling users to undertake process development, process improvement and product characterisation. It is one of the most well-equipped bioscience training facilities in the UK offering industry-leading facilities, equipment and resources for bioprocessing, biological imaging, genomics, proteomics, metabolomics, biosynthesis and bioinformatics.

The National Horizons Centre has already helped deliver a number of collaborative innovation projects, working alongside industrial partners including Lonza, UCB Pharma, Glythera, ITS, Bakels and Quorn.

The National Horizons Centre is fulfilling a key national role in delivering UK based multi-disciplinary innovation and research using advancements in biologics, informatics and big data to promote new thinking in biologics, health and digital health technologies.



European Union
European Regional Development Fund

| INNOVATION

The Tees Valley is a forward-thinking area that supports innovation and new initiatives. In an industry where research and innovation are key to development, the area is always looking at new opportunities to increase its offering in this capacity.

Teesside University, South Tees Hospitals NHS Foundation Trust and research and technology organisation TWI have formed a partnership to help develop new health technologies and solutions. The Tees Healthcare Innovation Partnership (T-HIP) builds on the Healthcare Innovation Centre (HIC) collaboration between TWI and Teesside University and aims to provide greater support and capacity for healthcare innovation in the Tees Valley.

It offers the technical facilities and space to develop and test new ideas and enables collaborative working between specialists in complementary disciplines. This model brings together the practical experience of expert clinicians and healthcare professionals with the wide-ranging and complementary skills of the academic and technology partners. This project will ensure that the

maximum benefit will be gained from the research and commercialisation opportunities.

The Durham Tees Valley Research Alliance (DTVRA) has been established by the County Durham and Darlington, North Tees and Hartlepool and South Tees NHS Foundation Trusts. It functions as a one single point of contact for study feasibility, review and set-up.

Importantly, it also provides an opportunity to focus and tackle the disease burden with access to a combined population of 1.5million, through progressing collaborative research projects of international importance with local universities, small and medium sized enterprises (SMEs) and commercial partners.



The proposed Business Central Two facility will include new state-of-the-art office and laboratory space. Built at Central Park, which is strategically located next to Darlington rail station and the East Coast Main Line, Business Central Two will also provide new occupiers with immediate access to the innovation and skills expertise at CPI and the National Horizons Centre, potentially seeding new collaborative growth opportunities.

Case Study

Experts at Teesside University and South Tees Hospitals NHS Foundation Trust have jointly developed a new software application to speed up the diagnosis and treatment of hepatitis and HIV patients. The software is currently undergoing pilot testing in several GP surgeries and, if successful, could ultimately lead to quicker diagnosis and treatment, improved patient outcomes and also reduce transmission of blood-borne viruses (BBVs). The software module is applied to the database of existing medical records and provides an automatic prompt to GPs and other healthcare workers each time a BBV test should be recommended for a patient, speeding up the process and potentially enabling quicker diagnosis and treatment. The technology won the 2018 Medipex NHS Innovation Award for Primary Care, as well as the Bright Ideas in Health Award for development of an innovative device or technology.





| INVEST TEES VALLEY

Invest Tees Valley is the Combined Authority's business investment team. There are financial incentives and support available for companies looking to locate in the region, such as the Northern Powerhouse Investment Fund and the Tees Valley Capital Grant Scheme.

The business investment team makes investing here easy and works with investors to understand their project parameters and identify the key risks. It provides advice and assistance to help mitigate those risks with the aim of finding solutions to reduce the capital and operational expenditure for potential investors.

The team can advise on funding streams to support capital investment and make introductions to our network, including strong connections with UK Government, cluster and innovation specialists, as well as skills development within local universities and colleges.

Being one of only eight areas in the UK to have a metro mayor and a devolution deal, the Tees Valley has a

competitive edge and investors can be confident that decision-making here is done with our local businesses in mind. Devolved decision-making helps us fulfil our potential and develop and nurture businesses in a way that will support them and the wider Tees Valley.

Significant funding has already been delivered to ensure the area has the infrastructure to support major investments. Over the next ten years the Tees Valley Combined Authority is investing £588million over ten years across six key themes. This investment in our transport, culture, skills, innovation, communities and businesses growth will make the Tees Valley an even better place to do business.





| ENJOY TEES VALLEY

The Tees Valley offers a great standard of living with a richly diverse landscape, from picturesque villages to charming market towns and a beautiful coastline to stunning countryside. Each of the five boroughs has unique strengths that make the Tees Valley greater than the sum of its parts.

Five distinct boroughs big on culture and adventure bursting with things to do and places to see. From dramatic hilltops to rugged coastlines, picturesque countryside to attractive villages, the Tees Valley may just surprise you.

Quality of life is good here because our people get more for their money. There is a superb variety of homes to suit most incomes. From country cottages to new builds and Victorian houses to executive apartments, there is something for everyone.

Nine out of ten Tees Valley primary schools are either good or outstanding and apprenticeships and support schemes create pathways for our young people.

The area is rich in culture and history with an arts offering that includes one of the UK's leading galleries for modern art, mima. It has a proud railway and maritime heritage and a packed programme of exciting events and festivals, including a spectacular international festival of outdoor art – the Stockton International Riverside Festival – and the increasingly popular artisan food market Orange Pip.

An adventure lover's paradise, you can surf on the waves at the coast, enjoy the spectacular countryside by foot or bike, enjoy a river boat ride, jet-ski, canoe, kayak, paddle-board or try out our Olympic standard white-water rafting course. We are also home to the only bridge in England that you can bungee jump off – the Transporter Bridge.

To find out more, go to EnjoyTeesValley.com – the Combined Authority's dedicated destination marketing service



| CONTACT



For more detailed information,
please get in touch with the
Business Investment Team

T: 01642 524400

E: info@teesinvest.com

www.teesinvest.com

INVEST | TEES VALLEY

